Mirum Pharmaceuticals (NASDAQ: MIRM) holder files Rule 144 sale notice

Rhea-AI Filing Summary

Mirum Pharmaceuticals shareholder Christopher Peetz has filed a Rule 144 notice to sell 9,108 shares of common stock. The planned sale, through Morgan Stanley Smith Barney on the NASDAQ around 02/02/2026, has an aggregate market value of $945,410.40, with 51,393,574 shares outstanding.

The shares to be sold were acquired on 01/31/2026 when restricted stock units vested under a registered plan as compensation for services to Mirum. The filing also notes earlier January 2026 sales of 7,098 and 6,831 shares of common stock for gross proceeds of $662,422.46 and $657,087.57, respectively.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC 1 New York Plaza, 8th Floor New York NY 10004	9108	945410.40	51393574	02/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/31/2026	Restricted Stock Units vesting under registered plan	Issuer			9108	01/31/2026	Compensation for services rendered to Issuer

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Christopher Peetz c/o Mirum Pharmaceuticals, Inc. 989 E Hillsdale Blvd., Suite 300 Foster City CA 94404	Common Stock	01/22/2026	7098	662422.46
Christopher Peetz c/o Mirum Pharmaceuticals, Inc. 989 E. Hillsdale Blvd., Suite 300 Foster City CA 94404	Common Stock	01/26/2026	6831	657087.57

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Mirum Pharmaceuticals (MIRM) Form 144 filed by Christopher Peetz disclose?

The Form 144 discloses a planned sale of 9,108 Mirum Pharmaceuticals common shares. The shares, valued at $945,410.40, are to be sold on NASDAQ through Morgan Stanley Smith Barney under Rule 144, following vesting of restricted stock units as compensation.

How many Mirum Pharmaceuticals (MIRM) shares are planned to be sold under this Rule 144 notice?

The notice covers a planned sale of 9,108 Mirum Pharmaceuticals common shares. These shares are listed with an aggregate market value of $945,410.40 and will be sold on the NASDAQ exchange through Morgan Stanley Smith Barney as broker.

How were the Mirum Pharmaceuticals (MIRM) shares in the Form 144 acquired?

The 9,108 Mirum Pharmaceuticals shares were acquired on 01/31/2026 through restricted stock units vesting under a registered plan. The filing states they represent compensation for services rendered to Mirum, rather than a cash purchase transaction by the shareholder.

What recent Mirum Pharmaceuticals (MIRM) share sales by Christopher Peetz are reported?

The filing reports two prior sales of Mirum common stock in January 2026. One sale on 01/22/2026 covered 7,098 shares for $662,422.46, and another on 01/26/2026 covered 6,831 shares for $657,087.57 in gross proceeds.

How many Mirum Pharmaceuticals (MIRM) shares are outstanding in this Form 144 filing?

The Form 144 states that 51,393,574 Mirum Pharmaceuticals common shares are outstanding. This figure provides context for the planned 9,108-share Rule 144 sale and the prior January sales disclosed in the same notice.

Which broker and exchange are involved in the Mirum Pharmaceuticals (MIRM) Rule 144 sale?

The planned sale will be executed through Morgan Stanley Smith Barney LLC. The Form 144 specifies that the 9,108 Mirum Pharmaceuticals common shares are expected to be sold on the NASDAQ stock market around 02/02/2026 under Rule 144.